Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo

Loading...
Loading...
  • Exelixis Inc EXEL announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS)
  • CONTACT-03 is sponsored by Roche Holdings AG RHHBY and co-funded by Exelixis.
  • The study evaluated Cabometyx (cabozantinib) combined with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear or non-clear renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy.
  • Three months ago, the companies disclosed a similarly disappointing outcome for the CONTACT-01 study.
  • Tecentriq plus Cabometyx failed to meet its primary endpoint of overall survival at the final analysis compared to chemotherapy. 
  • CONTACT-02, focused on metastatic castration-resistant prostate cancer, is slated to read out later this year.
  • The CONTACT-03 trial enrolled 522 patients with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy, either as part of a combination or as a monotherapy. 
  • More data will be presented at a medical meeting, Exelixis said.
  • Price Action: EXEL shares are down 1.89% at $16.86 on the last check Friday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...